Monday, April 20, 2015 5:59:16 PM
Look at the deal Caven cut. 7.5 million shares of common and 2.5 million of preferred. Caven takes companies with locked up pritability and through changes in management, marketing, product diversity , and operational changes to increase capacity or efficiency. Since PE money is equity and that equity is so expensive these turnarounds have to happen fast or the equity prefs eat you up. So PE guys operate in dog years and get merger and acquisition targets in as fast as they can.
Caven left a very lucrative world to join this company. Why? Because he believed he's going to make a killing, that's why.
Caven left a very lucrative world to join this company. Why? Because he believed he's going to make a killing, that's why.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
